drug
VABYSMO
updated 6mo agoby Genentech Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying VABYSMO
News(10)
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 20h ago
- J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trialBlackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setba…biospace · 22h ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 1d ago
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.biospace · 25d ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecificsGenentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.biospace · 1mo ago
- Merck sees pivotal victory for $3B eye disease prospectMerck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…fiercebiotech · 1mo ago
- Roche bets up to $1B to advance next-gen bispecifics with DualitasThe partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.biospace · 2mo ago
- Roche, Dualitas team up to find bispecific drugs for immune diseasesThrough a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.biopharma_dive · 2mo ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that